Cancer-associated fibroblasts thus maintain a close interaction with carcinoma cells promoting PI3K/AKT signalling while contributing to an ‘escape’ mechanism from the effects of erlotinib in PDAC. The gene discussed is AKT1; the disease is carcinoma.